

JC19 Rec'd PCT/PTO 27 NOV 2001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Claudia ULBRICH et al.  
Serial No.: New  
Filing Date: November 27, 2001  
For: MEDICAMENTS FOR THE IMMUNOTHERAPY OF MALIGNANT  
TUMORS

PRELIMINARY AMENDMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-identified application as follows:

IN THE SPECIFICATION

On page 1, immediately following the title, please insert the following sentence: --This is a 371 of PCT/EP01/08455 filed July 21, 2001, the disclosure of which is incorporated herein by reference.--

IN THE CLAIMS

Please amend claims 4, 7 through 11 as follows:

4. (amended) A medicament containing a composition according to claim 1.

7. (amended) The method according to claim 5, in which the differentiation of the monocytes into "immature" dendritic cells by

cytokines, IL-4 and GM-CSF with or without interferon-gamma.

8. (amended) The method according to claim 5, in which the maturing from "immature" to "mature" dendritic cells is induced by prostaglandin E<sub>2</sub> and TNF- $\alpha$  and/or IL-1 $\beta$  and IL-6 in addition to IL-4 and GM-CSF.

9. (amended) The method according to claim 5, in which the tumor cell suspension is prepared by isolating the optionally evaluating tumor material, which is then comminuted and transferred into a purified cell suspension.

10. (amended) The method according to claim 5, in which the tumor cell suspension is prepared by isolating and optionally evaluating autologous tumor material, which is then comminuted and transferred into a purified cell suspension.

11. (amended) The method according to claim 5, in which the expression of membrane-borne protein complexes is induced in the tumor cell suspension prior to said killing of the tumor cells.

**REMARKS**

The foregoing Preliminary Amendment is requested in order to delete the multiple dependent claims and avoid paying the multiple dependent claims fee.


Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

Early action on the merits is respectfully requested.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By



William E. Player

Reg. No. 31,409

400 Seventh Street, N.W.  
Washington, D.C. 20004-2201  
(202) 638-6666

Atty. Docket: P67344US0  
Date: November 27, 2001  
WEP/cmf

VERSION WITH MARKINGS TO SHOW CHANGES MADEIN THE CLAIMS

4. (amended) A medicament containing a composition according to claim 1 [at least one of claims 1 to 3].

7. (amended) The method according to claim 5 [and/or 6], in which the differentiation of the monocytes into "immature" dendritic cells by cytokines, IL-4 and GM-CSF with or without interferon-gamma.

8. (amended) The method according to claim 5 [at least one of claims 5 to 7], in which the maturing from "immature" to "mature" dendritic cells is induced by prostaglandin E<sub>2</sub> and TNF- $\alpha$  and/or IL-1 $\beta$  and IL-6 in addition to IL-4 and GM-CSF.

9. (amended) The method according to claim 5 [at least one of claims 5 to 8], in which the tumor cell suspension is prepared by isolating the optionally evaluating tumor material, which is then comminuted and transferred into a purified cell suspension.

10. (amended) The method according to claim 5 [at least one of claims 5 to 9], in which the tumor cell suspension is prepared by isolating and optionally evaluating autologous tumor material, which is then comminuted and transferred into a purified cell suspension.

11. (amended) The method according to claim 5 [at least one of claims 5 to 10], in which the expression of membrane-borne protein

complexes is induced in the tumor cell suspension prior to said killing of the tumor cells.